Sonen Capital LLC Has $841,000 Stock Position in Danaher Co. (NYSE:DHR)

Sonen Capital LLC raised its holdings in Danaher Co. (NYSE:DHRGet Rating) by 22.6% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,866 shares of the conglomerate’s stock after buying an additional 528 shares during the quarter. Sonen Capital LLC’s holdings in Danaher were worth $841,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Beaumont Financial Partners LLC grew its holdings in shares of Danaher by 2.6% during the 1st quarter. Beaumont Financial Partners LLC now owns 50,032 shares of the conglomerate’s stock worth $14,682,000 after purchasing an additional 1,265 shares in the last quarter. Waratah Capital Advisors Ltd. acquired a new stake in shares of Danaher during the 1st quarter worth approximately $8,138,000. Highlander Capital Management LLC grew its holdings in shares of Danaher by 100.0% during the 1st quarter. Highlander Capital Management LLC now owns 400 shares of the conglomerate’s stock worth $117,000 after purchasing an additional 200 shares in the last quarter. Teacher Retirement System of Texas lifted its position in shares of Danaher by 4.3% during the 1st quarter. Teacher Retirement System of Texas now owns 238,113 shares of the conglomerate’s stock worth $69,846,000 after buying an additional 9,760 shares during the period. Finally, Capital Advisors Ltd. LLC lifted its position in shares of Danaher by 25.9% during the 1st quarter. Capital Advisors Ltd. LLC now owns 1,429 shares of the conglomerate’s stock worth $419,000 after buying an additional 294 shares during the period. Institutional investors and hedge funds own 78.42% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, Director Walter G. Lohr sold 3,906 shares of the business’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $273.84, for a total value of $1,069,619.04. Following the sale, the director now directly owns 12,115 shares in the company, valued at $3,317,571.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Walter G. Lohr sold 3,906 shares of the company’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $273.84, for a total transaction of $1,069,619.04. Following the sale, the director now owns 12,115 shares in the company, valued at $3,317,571.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joakim Weidemanis sold 12,000 shares of the company’s stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $271.13, for a total value of $3,253,560.00. Following the sale, the executive vice president now owns 74,398 shares in the company, valued at approximately $20,171,529.74. The disclosure for this sale can be found here. Insiders own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Evercore ISI cut their target price on Danaher from $320.00 to $280.00 and set an “outperform” rating for the company in a research report on Tuesday, July 5th. Cowen cut their target price on Danaher to $340.00 in a research report on Friday, July 22nd. KeyCorp cut their price objective on Danaher from $345.00 to $325.00 and set an “overweight” rating for the company in a research report on Friday, July 22nd. Barclays lifted their price objective on Danaher from $290.00 to $310.00 in a research report on Friday, July 22nd. Finally, StockNews.com upgraded Danaher from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 30th. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $328.58.

Danaher Trading Up 0.4 %

Shares of Danaher stock traded up $1.05 during trading on Friday, reaching $290.00. 1,316,343 shares of the company were exchanged, compared to its average volume of 2,304,426. The company has a quick ratio of 1.32, a current ratio of 1.75 and a debt-to-equity ratio of 0.45. Danaher Co. has a twelve month low of $233.71 and a twelve month high of $333.96. The business has a 50-day moving average price of $261.98 and a 200-day moving average price of $268.32. The firm has a market capitalization of $210.96 billion, a price-to-earnings ratio of 34.16, a P/E/G ratio of 2.32 and a beta of 0.86.

Danaher (NYSE:DHRGet Rating) last announced its quarterly earnings data on Thursday, July 21st. The conglomerate reported $2.76 EPS for the quarter, topping analysts’ consensus estimates of $2.35 by $0.41. Danaher had a return on equity of 18.57% and a net margin of 20.61%. The business had revenue of $7.75 billion during the quarter, compared to analysts’ expectations of $7.29 billion. During the same period in the previous year, the firm earned $2.46 earnings per share. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. Sell-side analysts anticipate that Danaher Co. will post 10.39 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, July 29th. Shareholders of record on Friday, June 24th were paid a $0.25 dividend. The ex-dividend date was Thursday, June 23rd. This represents a $1.00 dividend on an annualized basis and a yield of 0.34%. Danaher’s payout ratio is 11.78%.

Danaher Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.